非酒精性脂肪性肝病与肝细胞恶性转化的关系

顾娟娟; 姚敏; 姚登福

doi:10.3969/j.issn.1001-5256.2016.03.037

非酒精性脂肪性肝病与肝细胞恶性转化的关系

DOI: 10.3969/j.issn.1001-5256.2016.03.037

南通大学附属医院临床医学研究中心

基金项目:

国家国际科技合作项目(2013DFA32150)；国家自然科学基金(81200634)；

详细信息

中图分类号: R575.5;R735.7
计量
- 文章访问数: 1489
- HTML全文浏览量: 28
- PDF下载量: 415
- 被引次数: 0
出版历程
- 出版日期: 2016-03-20

Association between nonalcoholic fatty liver disease and malignant transformation of hepatocytes

Center of Clinical Medicine, Affiliated Hospital of Nantong University

Research funding:

摘要

摘要:
非酒精性脂肪性肝病(NAFLD)是除酒精和其他明确的肝损伤因素所致的以弥漫性肝细胞大泡性脂肪变性为主,肝脏脂质蓄积过多的临床病理综合征,包括单纯性脂肪肝、演变的脂肪性肝炎和肝硬化。随着NAFLD发病率的不断上升,其在肝细胞癌(HCC)中的发病风险也在增加,但其确切的机制尚不清楚。总结了NAFLD中脂质积累、各种相关细胞、蛋白、激素、代谢产物等与肝细胞恶性转化之间关系,以及NAFLD、HCC和脂肪代谢三者间的联系,为临床上预防HCC提供新的思路。
- 脂肪肝 /
- 肝肿瘤 /
- 综述
Abstract:
Nonalcoholic fatty liver disease( NAFLD) is a clinicopathological syndrome characterized by diffuse macrovesicular steatosis and excessive lipid accumulation in the liver due to nonalcoholic reasons and other specific factors for liver injury,including simple fatty liver,nonalcoholic steatohepatitis,and liver cirrhosis. With the increasing incidence of NAFLD,the risk of hepatocellular carcinoma( HCC) is also increasing,but the exact mechanism remains unknown. This paper summarizes the roles of lipid accumulation,related cells,proteins,hormones,and metabolites in malignant transformation of hepatocytes,as well as the relationship between NAFLD,HCC,and lipid metabolism,and provides a new perspective for the prevention of HCC in clinical practice.
- fatty liver /
- liver neoplosms review /

HTML全文

参考文献(39)

[1]DING J,WANG H.Multiple interactive factors in hepatocarcinogenesis[J].Cancer Lett,2014,346(1):17-23.

[2]FAN JG,FARRELL GC.Epidemiology of non-alcoholic fatty liver disease in China[J].J Hepatol,2009,50(1):204-210.

[3]FAN JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].J Gastroenterol Hepatol,2013,28(Suppl 1):11-17.

[4]STICKEL F,HELLERBRAND C.Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma:mechanisms and implications[J].Gut,2010,59(10):1303-1307.

[5]de MINICIS S,MARZIONI M,BENEDETTI A,et al.New insights in hepatocellular carcinoma:from bench to bedside[J].Ann Transl Med,2013,1(2):15.

[6]LINHART KB,GLASSEN K,PECCERELLA T,et al.The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease[J].Hepatobiliary Surg Nutr,2015,4(2):117-123.

[7]JIANG CM,PU CW,HOU YH,et al.Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development[J].World J Gastroenterol,2014,20(44):16464-16473.

[8]YOON HJ,CHA BS.Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease[J].World J Hepatol,2014,6(11):800-811.

[9]BAFFY G,BRUNT EM,CALDWELL SH.Hepatocellular carcinoma in non-alcoholic fatty liver disease:an emerging menace[J].J Hepatol,2012,56(6):1384-1391.

[10]YAMASHITA T,HONDA M,TAKATORI H,et al.Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma[J].J Hepatol,2009,50(1):100-110.

[11]JIANG S,MINTER LC,STRATTON SA,et al.TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice[J].J Hepatol,2015,62(2):371-379.

[12]NAGOSHI S.Osteopontin:versatile modulator of liver diseases[J].Hepatol Res,2014,44(1):22-30.

[13]Mc KEE C,SIGALA B,SOEDA J,et al.Amphiregulin activates human hepatic stellate cells and is upregulated in non alcoholic steatohepatitis[J].Sci Rep,2015,5:8812.

[14]MIKURIYA Y,TASHIRO H,KOBAYASHI T,et al.Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease[J].Langenbecks Arch Surg,2015,400(4):471-476.

[15]WOLF MJ,ADILI A,PIOTROWITZ K,et al.Metabolic activation of intrahepatic CD8+T cell and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepato-cytes[J].Cancer Cell,2014,26(4):549-564.

[16]BIEGHS V,TRAUTWEIN C.Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease[J].Hepatobiliary Surg Nutr,2014,3(6):377-385.

[17]GENTRIC G,MAILLET V,PARADIS V,et al.Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease[J].J Clin Invest,2015,125(3):981-992.

[18]NOUREDDIN M,RINELLA ME.Nonalcoholic fatty liver disease,diabetes,obesity,and hepato-cellular carcinoma[J].Clin Liver Dis,2015,19(2):361-379.

[19]DUAN XY,ZHANG L,FAN JG,et al.NAFLD leads to liver cancer:do we have sufficient evidence?[J].Cancer Lett,2014,345(2):230-234.

[20]SORRENTINO P,D'ANGELO S,FERBO U,et al.Liver iron excess in patients with hepatocellular carcinoma developed on nonalcoholic steato-hepatitis[J].J Hepatol,2009,50(2):351-357.

[21]BA Q,HAO M,HUANG H,et al.Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies[J].Clin Cancer Res,2011,17(24):7625-7633.

[22]KIRSTEIN MM,VOGEL A.The pathogenesis of hepatocellular carcinoma[J].Dig Dis,2014,32(5):545-53.

[23]NISCHALKE HD,LUTZ P,KRMER B,et al.A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease[J].J Hepatol,2014,61(5):1073-1079.

[24]SUN C,FAN JG,QIAO L.Potential epigenetic mechanism in non-alcoholic fatty liver disease[J].Int J Mol Sci,2015,16(3):5161-5179.

[25]CERMELLI S,RUGGIERI A,MARRERO JA,et al.Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease[J].PLo S One,2011,6(8):e23937.

[26]TAKAKI Y,SAITO Y,TAKASUGI A,et al.Silencing of microRNA-122 is an early event during hepatocarcinogenesis from nonalcoholic steatohepatitis[J].Cancer Sci,2014,105(10):1254-1260.

[27]FRADES I,ANDREASSON E,MATO JM,et al.Integrative genomic signatures of hepatocellular carcinoma derived from nonalcoholic fatty liver disease[J].PLo S One,2015,10(5):e0124544.

[28]GAGGINI M,MORELLI M,BUZZIGOLI E,et al.Non-alcoholic fatty liver disease(NAFLD)and its connection with insulin resistance,dyslipidemia,atherosclerosis and coronary heart disease[J].Nutrients,2013,5(5):1544-1560.

[29]STARLEY BQ,CALCAGNO CJ,HARRISON SA.Nonalcoholic fatty liver disease and hepatocellular carcinoma:a weighty connection[J].Hepatology,2010,51(5):1820-1832.

[30]ROMEO S,KOZLITINA J,XING C,et al.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J].Nat Genet,2008,40(12):1461-1465.

[31]ODA K,UTO H,MAWATARI S,et al.Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease:a review of human studies[J].Clin J Gastroenterol,2015,8(1):1-9.

[32]ALISI A,CECCARELLI S,PANERA N,et al.Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis[J].Front Cell Infect Microbiol,2012,2:132.

[33]TAKEUCHI M,SAKASAI-SAKAI A,TAKATA T,et al.Serum levels of toxic AGEs(TAGE)may be a promising novel biomarker in development and progression of NASH[J].Med Hypotheses,2015,84(5):490-493.

[34]BERLANGA A,GUIU-JURADO E,PORRAS JA,et al.Molecular pathways in non-alcoholic fatty liver disease[J].Clin Exp Gastroenterol,2014,7:221-239.

[35]STREBA LA,VERE CC,ROGOVEANU I,et al.Nonalcoholic fatty liver disease,metabolic risk factors,and hepatocellular carcinoma:an open question[J].World J Gastroenterol,2015,21(14):4103-4110.

[36]YOSHIMOTO S,LOO TM,ATARASHI K,et al.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J].Nature,2013,499(7456):97-101.

[37]PARK EJ,LEE JH,YU GY,et al.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6and TNF expression[J].Cell,2010,140(2):197-208.

[38]KAR P.Risk factors for hepatocellular carcinoma in India[J].J Clin Exp Hepatol,2014,4(Suppl 3):s34-s42.

[39]RAFF EJ,KAKATI D,BLOOMER JR,et al.Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases[J].J Clin Transl Hepatol,2015,3(1):9-16.

施引文献

资源附件(0)

访问统计